Literature DB >> 10482181

Implications of cell death regulation in the pathogenesis and treatment of prostate cancer.

E M Bruckheimer1, B T Gjertsen, T J McDonnell.   

Abstract

Although the phenomenon of programed cell death, or apoptosis, has been recognized for many years, interest in the clinical implications of apoptotic cell death has not been widely apparent until recently. It is now established that the products of at least some oncogenes and tumor suppressor genes are able to regulate the rates of apoptosis as well as proliferation in tumor cell populations. In fact, it appears that evasion of deletion via apoptotic cell death may be a requisite event in the development of many malignant neoplasms. Molecular alterations that occur at high frequency in the pathogenesis of prostate cancer often involve genes implicated in the regulation of cell death. There is now ample reason to speculate that the susceptibility of individual malignant neoplasms to undergo apoptosis in response to a given therapeutic intervention may be a useful parameter in predicting therapeutic response. This realization has profound implications with respect to the design and implementation of treatment strategies for prostate cancer based on the biology of this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482181

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  5 in total

1.  Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound.

Authors:  Fuminori Teraishi; Shuhong Wu; Satoshi Inoue; Lidong Zhang; John J Davis; Wei Guo; Fengqin Dong; Bingliang Fang
Journal:  Prostate       Date:  2006-03-01       Impact factor: 4.104

Review 2.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

3.  PTEN mutation spectrum in breast cancers and breast hyperplasia.

Authors:  Julun Yang; Yan Ren; Li Wang; Baolin Li; Yue Chen; Wenxing Zhao; Wenmang Xu; Tao Li; Fang Dai
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-19       Impact factor: 4.553

4.  Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.

Authors:  Ying Chen; Yong Cao; Danlei Yang; Kaiyan Li; Zhengyun Wang; Jing Zhu; Hansvin Bunjhoo; Shengdao Xiong; Yongjian Xu; Weining Xiong
Journal:  Exp Ther Med       Date:  2011-11-16       Impact factor: 2.447

5.  ARP2, a novel pro-apoptotic protein expressed in epithelial prostate cancer LNCaP cells and epithelial ovary CHO transformed cells.

Authors:  Jaime Mas-Oliva; Enrique Navarro-Vidal; Juana Virginia Tapia-Vieyra
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.